ArticleInternational ophthalmology2026
Changes in corneal and lenticular transparency in active and inactive Graves' Ophthalmopathy: a comparative densitometric study.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to compare corneal and lens densitometry (CD and LD) values between active and inactive Graves Ophthalmopathy (GO) and Grave's Disease (GD) patients without ophthalmic involvement and healthy controls.
methodsThis cross-sectional clinical study included 22 patients with active GO with bilateral ocular involvement (group 1), 36 patients with inactive GO (group 2), 54 patients with GD but without ophthalmopathy (group 3) and 30 age- and gender-matched healthy controls (group 4). All participants underwent comprehensive ophthalmic examination, followed by corneal and lens densitometry assessment using the Pentacam HR imaging system (Oculus Inc., Wetzlar, Germany).
resultsComparative analysis revealed statistically significant differences (p < 0.05) in CD values among the groups across all layers, except for the anterior 10-12 mm (p = 0.117), posterior 0-2 mm (p = 0.185), and posterior 2-6 mm zones (p = 0.099). Active GO patients showed the highest CD values, followed by inactive GO, non-ophthalmopathy GD patients, and healthy controls, respectively. Additionally, CD-mean, CD-SD and CD-max parameters showed statistically significant differences between the groups (all p < 0.05), with active GO demonstrating significantly higher values than other groups. Regarding LD, LD-mean, LD-SD, and LD-max values were significantly higher in all Grave's disease-related groups compared with the control group (p < 0.001). CONCLUSıON: Our study shows that lenticular and corneal clarity is significantly reduced in GO patients, especially during the active period. These findings suggest that Pentacam could be used as a rapid, reliable and non-invasive tool for the early detection of deterioration in corneal and lenticular transparency in these patients.
Indexed as
Identifiers
41701259What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.